Browsing Category

65295 posts
BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations

BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations

Key points BofA Securities hosted its fourth annual Asia Alternatives Forum, bringing…

Traveloka 6.6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelers

Traveloka’s 6.6 Mid Year Sale Unlocks $66 Sitewide Discounts and 1-for-1 Attraction…

Deloitte appoints Robert Hillard as Asia Pacific Chief Executive Officer

HONG KONG, June 1, 2026 /PRNewswire/ — Deloitte Asia Pacific today announced…
UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities

UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities

SINGAPORE, June 1, 2026 /PRNewswire/ — UOB and global technology corporation FPT have…

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 SubgroupsIn first-line non-small cell…

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, June 1, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code:…
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety…
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a…